SynthesisNeurosurgical review2026
Systemic therapy in the treatment of recurrent or refractory intracranial meningiomas: A systematic review and individual patient data meta-analysis.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent or refractory meningiomas pose major therapeutic challenges once surgical and radiotherapeutic options are exhausted. The role and comparative effectiveness of systemic pharmacologic therapies remain unclear. This study evaluated survival outcomes and toxicity profiles of systemic agents used in adults with recurrent intracranial meningiomas. A systematic search of PubMed, Embase, and Web of Science (through November 2024) followed PRISMA-IPD guidelines. Eligible studies included adults with WHO grades I-III meningiomas treated with systemic agents for recurrent disease and reporting reconstructable time-to-event data. Individual patient data and digitized Kaplan–Meier estimates were pooled. Outcomes included progression-free survival (PFS), overall survival (OS), and treatment-related toxicity. Twenty-five studies (484 patients) were included. Across systemic agents, outcomes predominantly reflected disease stabilization rather than objective tumor regression. Hydroxyurea (n = 8) was most frequently evaluated, followed by bevacizumab (5), somatostatin analogues (5), interferon-α (3), PD-1/PD-L1 inhibitors (2), and tyrosine kinase inhibitors (2). Median PFS varied widely by WHO grade, with longer PFS generally observed in grade 1 tumors. Interferon-α and somatostatin analogs demonstrated longer PFS in grade 1 compared with higher-grade tumors Median OS ranged from 8 to 32 months without grade-specific differences. Toxicity profiles differed by agent: hydroxyurea was associated with frequent hematologic adverse effects (67.4%,), while bevacizumab and somatostatin analogs were generally well tolerated with low discontinuation rates. Hydroxyurea, interferon-α, and somatostatin analogues offer modest disease stabilization, particularly in lower-grade tumors, with generally manageable toxicity. These findings provide pooled, non-comparative benchmark reference ranges for future systemic therapy trials in recurrent/refractory meningioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.